Suresh T. Chari
苏雷什·查里
MD
Professor of Medicine; Director, Pancreatic Cancer Early Detection Program医学教授；胰腺癌早期检测项目主任
👥Biography 个人简介
Suresh T. Chari, MD is a Professor of Medicine at MD Anderson Cancer Center and one of the world's foremost authorities on early detection of pancreatic cancer. His pioneering work established the connection between new-onset diabetes and undiagnosed pancreatic cancer, leading to the development of the Enriching New-Onset Diabetes for Pancreatic Cancer (END-PAC) scoring model that is now used in prospective surveillance studies. He is a principal investigator in PRECEDE, the first multinational consortium dedicated to pancreatic cancer early detection in high-risk individuals.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
New-Onset Diabetes as a PDAC Warning Sign
Demonstrated that new-onset diabetes after age 50 is a marker of occult pancreatic cancer in a significant proportion of patients, developing the END-PAC model to identify which new diabetics warrant imaging, with prospective validation studies ongoing.
CA19-9 and Multi-Analyte Biomarker Panels
Led systematic studies defining the sensitivity, specificity, and optimal clinical application of CA19-9 in early detection settings, and contributed to the development of multi-marker liquid biopsy panels combining CA19-9 with ctDNA and protein biomarkers.
PRECEDE Consortium Leadership
Co-founded and leads the international PRECEDE (Pancreatic Cancer Early Detection) consortium, coordinating high-risk individual surveillance across 30+ institutions and building the largest biospecimen repository for PDAC early detection research.
Representative Works 代表性著作
New-Onset Diabetes: A Potential Clue to the Early Diagnosis of Pancreatic Cancer
Lancet Oncology (2019)
Landmark review synthesizing evidence for new-onset diabetes as an early manifestation of PDAC and proposing a clinical model for enriching surveillance populations.
Validation of a Multi-Analyte Blood Test for Early Pancreatic Cancer Detection: The PRECEDE Cohort
Journal of Clinical Oncology (2024)
Prospective validation of a blood-based multi-biomarker panel in the PRECEDE cohort, demonstrating superior performance over CA19-9 alone for detecting early-stage PDAC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 苏雷什·查里 的研究动态
Follow Suresh T. Chari's research updates
留下邮箱，当我们发布与 Suresh T. Chari（The University of Texas MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment